Avanafil
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Avanafil Product Information
Avanafil is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Avanafil. The product is supplied by Clearsynth under CAT No. CS-O-05671.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Avanafil
CAS No.
330784-47-9
CAT No.
CS-O-05671
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C23H26ClN7O3
Molecular Weight
483.95
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Avanafil is supplied with detailed characterization data compliant with regulatory guideline. Avanafil can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Avanafil.
Overview
"Avanafil is an orally available phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Avanafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cav"
Synonyms
Avanafil
Application Notes
"Avanafil is an orally available phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Avanafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cav"
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.